Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Australis Capital Inc. (AUSAF)
Las Vegas, NV, US
Australis Capital Inc. functions as a cannabis enterprise, actively pursuing both cannabis and horticultural ventures. These projects span a broad international landscape, encompassing the United States, Canada, Denmark, Finland, Iceland, Germany, the Netherlands, Bahrain, the United Arab Emirates, Southeast Asia, Australia, and numerous other global territories. The firm's corporate offices are located in Las Vegas, Nevada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -80.00% | -80.00% | -80.00% | -93.33% | -99.89% | -99.99% | -99.99% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+955.8% ★ Q1'22: +575.8% (vs Q1'21)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-14.3% Q1'22: -793.6% (vs Q1'21)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-190.7% Q1'22: -172.0% (vs Q1'21)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-204.6% Q1'22: -233,361.9% (vs Q1'21)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-40.4% Q1'22: -113,684.3% (vs Q1'21)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+39.7% Q1'22: +42.5% (vs Q1'21)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.17× Q1'22: 0.00× (vs Q1'21)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Wilson | Chief Financial Officer | 246.1K | male |
| Terrance R. Booth | Chief Executive Officer & Director | 222.1K | male |
| W. Campbell Birge | Strategic Advisor | 72.2K | male |
| Jason Ronald Bradley Dyck | Chief Science Officer, Chairman of Scientific Advisory Board & Director | 18.0K | — |
| Roger Sykes | Chief Operating Officer | — | male |
| Randon Marcos | Director of Business Development | — | male |
| Marc Lakmaaker | Senior Vice President of Communications & Capital Markets | — | male |
| Paul E. Larsen | General Counsel | — | male |
| Fausto Aceituno Aceituno | Chief Marketing Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AUSAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
